Skip to main content

Peer Review reports

From: A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer

Original Submission
31 May 2022 Submitted Original manuscript
8 Jun 2022 Reviewed Reviewer Report - Jieqiong Liu
20 Jun 2022 Reviewed Reviewer Report
17 Jul 2022 Author responded Author comments - Qingyuan Zhang
Resubmission - Version 2
17 Jul 2022 Submitted Manuscript version 2
27 Jul 2022 Reviewed Reviewer Report - Jieqiong Liu
4 Aug 2022 Author responded Author comments - Qingyuan Zhang
Resubmission - Version 3
4 Aug 2022 Submitted Manuscript version 3
Publishing
12 Aug 2022 Editorially accepted
3 Oct 2022 Article published 10.1186/s12916-022-02527-6

You can find further information about peer review here.

Back to article page